Table 2.

Comparison of end-of-life decision and their intention between 2022 overseas France and 2010 mainland

			Overseas France 2022			Mainland France 2010
			n	% weighted	Confidence intervall 95%	n	% weighted	Confidence interval 95%
Medical end-of-life practice knowing that they possibly or certainly hastened death
Treatment withheld			450	40.58	[37.41–43.75]	1608	38.95	[37.45–40.46]
		knowing that the decision may hasten death	438	39.36	[36.21–42.51]	1539	37.29	[35.80-38.78]
		with the intention of hastening death	12	1.22	[0.46–1.98]	69	1.66	[1.27–2.06]
Treatment withdrawn			182	14.94	[12.76–17.12]	544	12.99	[11.96–14.01]
		knowing that the decision may hasten death	169	13.99	[11.86–16.12]	475	11.36	[10.39–12.33]
		with the intention of hastening death	13	0.96	[0.40–1.51]	69	1.62	[1.24–2.01]
Intensification of treatment to alleviate pain and/or symptoms *			444	38.86	[35.73–41.99]	1401	33.73	[32.27–35.18]
		knowing that the decision may hasten death*	425	37.36	[34.25–40.46]	1344	32.35	[30.91–33.79]
		with the intention of hastening death	19	1.50	[0.78–2.23]	57	1.38	[1.02–1.74]
Deep and continuous sedation until death			158	13.31	[11.17–15.46]
Use of drugs to deliberate end life			17	1.32	[0.64–2.01]	36	0.92	[0.62–1.22]
		at patient’s request	5	0.35	[0.04–0.67]	10	0.26	[0.10–0.4]
Medical decision without any intention regarding death
	Treatment withheld		84	8.09	[6.28–9.90]	329	7.93	[7.10–8.77]
	Treatment withdrawn		19	1.33	[0.71–1.94]	89	2.09	[1.66–2.52]
	intensification of treatment to alleviate symptoms with medication with opioids or benzodiazepines		114	11.47	[9.30-13.64]	395	9.42	[8.53–10.32]
	intensification of treatment to alleviate symptoms with medication other than opioids or benzodiazepines*		22	2.00	[1.11–2.88]	199	4.87	[4.20–5.53]
Life prolonging treatment			398	34.83	[31.78–37.88]	1554	36.96	[35.47–38.44]
None of the investigated decisions			176	17.68	[15.12–20.23]	735	18.75	[17.52–19.97]